Neurocritical Care NCS Guideline 2026 GRADE Methodology

Guidelines for Neuroprognostication in Critically Ill Adults with Acute Ischemic Stroke

Evidence-based clinical practice guideline from the Neurocritical Care Society, addressing prognostic predictors and multivariate prediction models for functional outcome in ICU-admitted AIS patients

Published
6 April 2026
Journal
Neurocritical Care
Evidence
518 Articles Reviewed
Authors
Mainali et al. + 19 Experts
Focus
Functional Outcome @ 3 Months
📑 Table of Contents
1 Background & Rationale
2 Methodology
3 Predictors Evaluated
4 Key Findings & Recommendations
5 Clinical Prediction Models
6 Key Principles & Limitations
7 Clinical Take-Home Points
1
Background & Rationale
Why this guideline was created

Why Neuroprognostication Matters in AIS

Acute ischemic stroke (AIS) is a leading cause of death and disability worldwide. Approximately 10–20% of AIS patients require admission to an intensive care unit (ICU) for management of life-threatening complications.

🏥 Disorders of consciousness
🧠 Cerebral edema & herniation risk
❤️ Cardiopulmonary complications
🔧 Post-procedural care (post-thrombectomy, post-CEA)
Guideline Objective

To provide evidence-based recommendations on the reliability of individual predictors and multivariate prediction models for functional outcome at 3 months in critically ill adults with AIS — specifically for use when counseling patients and their surrogates.

Critical Knowledge Gap

Prior to this guideline, there was no standardized, GRADE-based framework for neuroprognostication in this specific population. Most existing evidence comes from general AIS cohorts and cannot be directly applied to the critically ill.

2
Methodology
GRADE-based narrative systematic review

How the Evidence Was Evaluated

This guideline used a narrative systematic review with GRADE methodology — the gold standard for clinical practice guideline development. Given expected heterogeneity in prognosis literature, a narrative (rather than meta-analytic) approach was chosen.

📊 PRISMA Flow

Initial librarian search: 20 February 2019 (covering 1946–2019) across MEDLINE/PubMed, EMBASE, Web of Science, Cochrane. Updated searches: 1 August 2022 and 5 February 2024.

Article Screening Criteria (Exclusions)

Criterion Reason
Sample size < 100 adult patients Insufficient statistical power for reliable prediction
TIA and/or mild stroke only Not representative of critically ill AIS population
Highly selected subgroups (e.g., periprocedural stroke) Indirectness — limits generalizability
Predictors not evaluated in multivariate analysis Inability to isolate independent effect
Genetic polymorphism predictors Not clinically applicable at bedside
Prediction models not reporting discrimination Cannot assess model performance

Risk of Bias Assessment

⚖️
QUIPS Instrument

Used for studies of individual prognostic variables

⚖️
PROBAST Instrument

Used for studies of clinical prediction models

Self-Fulfilling Prophecy — Special Concern

The guideline specifically assessed risk of bias from self-fulfilling prophecy — where knowledge of a poor prognostic predictor leads clinicians to withdraw life-sustaining treatment, thereby causing the predicted poor outcome. Three specific domains were evaluated: (1) treatment suspension policy, (2) clinician blinding to predictor, (3) systematic use of predictor for prognostication during the study period.

Outcomes Rated as Critical

Topic experts and a patient/family representative rated outcomes on GRADE 1–9 scale. Outcomes with median rating 7–9 were considered "critical."

Functional outcome (mRS) — primary endpoint
⚠️ Quality of life — insufficient evidence
⚠️ Cognitive function — insufficient evidence
⚠️ Depression — insufficient evidence
3
Predictors Evaluated
9 clinical variables + 4 prediction models

Clinical Variables Examined

The guideline selected predictors based on clinical relevance and the presence of an appropriate body of literature. A total of 9 clinical variables and 4 clinical prediction models were systematically evaluated.

#1 Age
#2 NIHSS on admission
#3 Blood glucose
#4 Cerebral collateral circulation status
#5 Hypertension
#6 Infarct size
#7 History of previous stroke
#8 Revascularization status
#9 Early neurological improvement (ENI)

Clinical Prediction Models Examined

ASTRAL Score

Acute Stroke Registry and Analysis of Lausanne

Age
NIHSS on admission
Acute glucose
Stroke onset to admission time
Altered consciousness
Right-sided infarction
DRAGON Score

Dense Artery, mRS, Age, Glucose, Onset-to-Treatment, NIHSS

Dense cerebral artery sign
Pre-stroke mRS
Age
Glucose
Onset-to-treatment time
NIHSS
iScore

Ischemic Stroke Predictive Risk Score

Age
Sex
NIHSS
Risk factors (AF, CHF, cancer, renal failure)
Lacunar infarct pattern
THRIVE Score

Totaled Health Risks in Vascular Events

Age
NIHSS
Cardiovascular risk factors (HTN, DM, AF)
⚠️ Important Methodological Limitation

Indirectness was a pervasive issue. Most studies of predictors following AIS were not limited to critically ill ICU patients. Therefore, the body of evidence was downgraded for indirectness across most PICOTS questions. Findings from general AIS populations may not fully apply to the sickest patients.

4
Key Findings & Recommendations
What the evidence actually supports

Summary of Key Recommendations

The following recommendations are primarily focused on prediction of functional outcome (mRS at 3 months). The guideline intentionally avoids recommendations for predicting mortality alone, due to high self-fulfilling prophecy bias in that literature.

NIHSS on Admission
Moderate Evidence

Higher NIHSS scores are associated with worse functional outcomes. However, the quality of evidence is limited by indirectness (most studies from general AIS, not specifically ICU patients). Use as one component of a multimodal prediction approach, not in isolation.

🔄
Revascularization Status
Moderate Evidence

Failure to achieve successful reperfusion (either via IV tPA, mechanical thrombectomy, or both) is associated with worse functional outcomes. Successful revascularization = stronger predictor when achieved.

📈
Early Neurological Improvement (ENI)
Moderate Evidence

ENI (typically defined as ≥4-point improvement on NIHSS at 24–72 hours, or reaching 0–1) is a robust predictor of good functional outcome. Absence of ENI portends poorer outcomes.

🧬
Cerebral Collateral Circulation Status
Limited Evidence

Better collateral circulation on imaging (CTA or conventional angiography) is associated with smaller infarct size and better outcomes. However, evidence quality is low due to variability in assessment methods and study populations.

🩺
Infarct Size
Limited Evidence

Larger infarct volume on imaging is associated with worse outcomes, but studies varied widely in how and when infarct size was measured. No consensus on a specific threshold for prognostication in ICU patients.

🧓
Age
Moderate Evidence

Advanced age is associated with worse functional outcomes post-AIS. However, age alone should never be used as a sole predictor. Combine with other clinical and imaging variables for prognostication.

Variables With Insufficient Evidence

❌ Cannot Recommend

The following were rated as critical outcomes by experts but had insufficient evidence to support any recommendation:

Blood glucose — hyper/hypoglycemia studied but conflicting data
Hypertension history — inconsistent definitions and timing
History of previous stroke — limited independent predictive value in multivariate models

Mortality Prediction — Not Recommended

🚫 No Single Variable Recommended for Mortality Prediction

The risk of self-fulfilling prophecy bias was deemed too high to recommend any single clinical variable for predicting death when "all available means of life support are used, indefinitely and without limitation." Supplementary data addresses mortality briefly but it was not a primary focus.

5
Clinical Prediction Models
How the 4 scores performed

Model Performance Summary

All four clinical prediction models were evaluated for discrimination (ability to separate those with good vs. poor outcomes) using standard metrics like C-statistic / AUC. However, all models showed significant limitations when applied to ICU-level critically ill patients.

⚠️ Critical Limitation of All Models

None of the prediction models (ASTRAL, DRAGON, iScore, THRIVE) were developed or validated specifically in critically ill AIS patients. Their original development cohorts predominantly included patients from general stroke units and registries. When applied to ICU patients, calibration may be poor — predicted probabilities often overestimate or underestimate actual outcomes in this sicker subgroup.

Model AUC Range Reported ICU Applicability Key Limitation
ASTRAL 0.75–0.85 ⚠️ Moderate Tested mainly in general AIS; lacks ICU-specific validation
DRAGON 0.78–0.88 ⚠️ Moderate Includes pre-stroke mRS; performs well for 3-month outcome in general AIS
iScore 0.72–0.82 ⚠️ Low-Moderate Includes comorbidities; developed from Canadian Stroke Registry
THRIVE 0.68–0.80 ⚠️ Low Simplified model; limited discrimination in ICU populations

Guideline Position on Models

✅ Practical Recommendation

These models can serve as adjunctive tools in the prognostic assessment of critically ill AIS patients, but should NOT replace clinical judgment or be used in isolation. They are best used within a multimodal, multidisciplinary prognostication framework that includes clinical examination, neuroimaging, neurophysiology (when available), and ongoing reassessment.

Functional Outcome Assessment

The majority of studies used the modified Rankin Scale (mRS), ranging from 0 (asymptomatic) to 6 (death). The guideline used an inclusive definition of good/poor outcome encompassing all mRS thresholds described in the literature — a deliberate choice given variability in how studies defined "good" vs. "poor" outcome.

mRS 0–1 Good outcome (no symptoms / no significant disability)
mRS 0–2 Good outcome (disability-free / slight disability)
mRS 3–5 Poor outcome (moderate to severe disability)
mRS 6 Death
6
Key Principles & Limitations
What this guideline does and does not tell us

Broad Principles of Neuroprognostication

Beyond specific variable recommendations, the guideline identified several GRADE "Good Practice Statements" — principles so fundamental they don't require formal evidence grading but represent current standard of care:

🗣️
Principle 1 — Communication

Neuroprognostication discussions should be honest, transparent, and calibrated. Avoid false optimism or unwarranted pessimism. Use probabilistic language ("chance of recovery is approximately X%") rather than deterministic statements.

👥
Principle 2 — Shared Decision-Making

Prognostic information should be presented to patients (if capable) and surrogates within a shared decision-making framework. Goals of care should be revisited repeatedly over time — prognosis is not static.

🔄
Principle 3 — Dynamic Reassessment

Neurological prognosis in AIS evolves over days to weeks. Single-timepoint predictions are insufficient. Serial clinical examinations, repeat neuroimaging, and neurophysiological studies (when indicated) should inform ongoing prognostic assessment.

👨‍⚕️
Principle 4 — Multidisciplinary Approach

Neuroprognostication should involve multiple specialties: neurology, neurocritical care, neurosurgery, rehabilitation medicine, nursing, and palliative care when appropriate. No single variable or model should drive decisions in isolation.

Major Limitations of This Guideline

Limitation Impact
Indirectness — most evidence from general AIS, not ICU-specific populations Recommendations may overestimate or underestimate true predictive value in ICU patients
Variable outcome definitions across studies (mRS thresholds) Limited ability to perform meta-analysis; heterogeneity in findings
Self-fulfilling prophecy in mortality literature Unable to make reliable recommendations for mortality prediction alone
No ICU-specific prediction models available Existing models have limited calibration in critically ill AIS population
Patient-centered outcomes (QoL, cognition, depression) — insufficient data Recommendations limited to functional outcome (mRS)
7
Clinical Take-Home Points
What every neuro-intensivist should remember

Bottom Line — 7 Clinical Pearls

1
Use multimodal assessment — No single predictor (NIHSS, age, infarct size, or any model score) is reliable enough alone. Combine clinical, imaging, and neurophysiological data.
2
Serial reassessment is key — Prognosis changes over time. What looks grim at day 2–3 may improve significantly. Avoid premature prognostic declarations.
3
Early neurological improvement (ENI) is a strong positive predictor — Document and communicate ENI clearly to surrogates as a favorable sign.
4
Failed revascularization = worse outcome signal — But it's a signal, not a verdict. Still requires integration with other factors.
5
Prediction models (ASTRAL, DRAGON, iScore, THRIVE) are adjuncts only — They can inform discussions but should not replace clinical judgment, especially in ICU patients outside their validation cohorts.
6
Avoid mortality-only prognostication — The self-fulfilling prophecy is real. Focus discussions on functional outcome and goals of care, not just "will they survive."
7
Communicate with calibrated probabilistic language — "Studies suggest approximately X% of patients with this clinical picture achieve functional independence" is more honest and useful than "they won't recover."

🔬 Future Directions — What This Guideline Identifies as Needed

ICU-specific prediction models — none currently exist with adequate ICU validation
Prospective studies in AIS-ICU patients with blinding to predictors to reduce self-fulfilling prophecy
Patient-centered outcomes research — QoL, cognitive function, depression post-ICU in AIS survivors
Standardized timing of prognostic assessment in the ICU course
Biomarker studies (serum, CSF, neuroimaging) specifically in critically ill AIS cohorts